Abstract
Purpose
The selection of appropriate endpoints is crucial for the evaluation of clinical benefits and approval of novel anticancer agents. To our knowledge, this is the first study to evaluate endpoint selection and the shift in trends in phase II and phase III trials of advanced breast cancer treatment.
Methods
All phase II and phase III trials of advanced breast cancer registered in the ClinicalTrials.gov registry between October 2000 and September 2012 were included in our study. Two study periods were considered for comparison: October 2000 to September 2007 (cohort A) and October 2007 to September 2012 (cohort B). Information on primary and secondary outcome measures, as well as trial characteristics, was extracted by two independent reviewers.
Results
Of the 398 phase II and 120 phase III trials, the most frequently intended primary endpoint was progression-free survival (phase II: 28.1 %; phase III: 50.0 %). For phase II trials, a shifting trend in primary outcome was observed from cohort A to cohort B: the use of objective response rate, the most frequently intended primary outcome, significantly declined (cohort A: 60.6 %; cohort B: 39.0 %; P < 0.001), while the use of progression-free survival significantly increased (cohort A: 35.9 %; cohort B: 66.1 %; P < 0.001).
Conclusions
Progression-free survival is the most frequently intended primary outcome measure in phase II and phase III trials of advanced breast cancer treatment, with a shifting trend observed from objective response rate to progression-free survival in phase II trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Cancer Society (2015) Cancer Facts & Figures 2015. American Cancer Society, Inc. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed 23 Feb 2015
Becker JE, Krumholz HM, Ben-Josef G, Ross JS (2014) Reporting of results in ClinicalTrials.gov and high-impact journals JAMA 311:1063–1065 doi:10.1001/jama.2013.285634
Booth CM, Eisenhauer EA (2012) Progression-free survival: meaningful or simply measurable? J Clin Oncol 30:1030–1033. doi:10.1200/jco.2011.38.7571
Bottomley A (2002) The cancer patient and quality of life. Oncologist 7:120–125. doi:10.1634/theoncologist.7-2-120
Bottomley A, Therasse P (2002) Quality of life in patients undergoing systemic therapy for advanced breast cancer. Lancet Oncol 3:620–628. doi:10.1016/S1470-2045(02)00876-8
Bradbury P, Seymour L (2009) Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated endpoint? Cancer journal (Sudbury, Mass) 15:354–360 doi:10.1097/PPO.0b013e3181b9c506
Bruzzi P, Mastro LD, Sormani MP et al (2005) Objective response to chemotherapy as a potential surrogate endpoint of survival in metastatic breast cancer patients. J Clin Oncol 23:5117–5125. doi:10.1200/jco.2005.02.106
Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. J Clin Oncol 26:1987–1992. doi:10.1200/jco.2007.10.8407
Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon J-P, Piedbois P (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218–5224. doi:10.1200/jco.2007.11.8836
Chan AW, Altman DG (2005) Identifying outcome reporting bias in randomised trials on pubmed: review of publications and survey of authors. BMJ 330:753–756. doi:10.1136/bmj.38356.424606.8F
Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291:2457–2465. doi:10.1001/jama.291.20.2457
Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart MJ (2015) A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Ann Oncol doi:10.1093/annonc/mdv249
Cohen SJ, Punt CJ, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221. doi:10.1200/JCO.2007.15.8923
Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791
DeAngelis CD, Drazen JM, Frizelle FA et al (2005) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Arch Otolaryngol Head Neck Surg 131:479–480. doi:10.1001/archotol.131.6.479
Di Leo A, Bleiberg H, Buyse M (2003) Overall survival is not a realistic endpoint for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 21:2045–2047. doi:10.1200/JCO.2003.99.089
Dowlati A, Fu P (2008) Is response rate relevant to the phase II trial design of targeted agents? J Clin Oncol 26:1204–1205. doi:10.1200/jco.2007.15.2827
Ellis LM, Bernstein DS, Voest EE et al (2014) American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 32:1277–1280. doi:10.1200/jco.2013.53.8009
European Medicines Agency (2013) Guideline on the evaluation of anticancer medicinal products in man. www.ema.europa.eu. Accessed 20 June 2016
George SL (2007) Response rate as an endpoint in clinical trials. J Natl Cancer Inst 99:98–99. doi:10.1093/jnci/djk024
Ghimire S, Kyung E, Kim E (2013) Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer. Lung 191:313–319. doi:10.1007/s00408-013-9479-z
Glas HE, Glass LM, DiFrancesco JJ (2014) ClinicalTrials. gov an underutilized source of research data about the design and conduct of commercial clinical trials therapeutic innovation & regulatory Science:2168479014551643
Gourgou-Bourgade S, Cameron D, Poortmans P et al (2015) Guidelines for time-to-event endpoint definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)dagger. Ann Oncol 26:873–879. doi:10.1093/annonc/mdv106
Hirsch BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chiswell K, Schulman KA, Dilts DM, Abernethy AP (2013) Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov JAMA. Intern Med 173:972–979. doi:10.1001/jamainternmed.2013.627
Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JAW et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132. doi:10.1200/jco.2006.10.3523
Huic M, Marusic M, Marusic A (2011) Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy. PLoS One 6:e25258. doi:10.1371/journal.pone.0025258
Johnson JR, Williams G, Pazdur R (2003) Endpoints and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404–1411. doi:10.1200/jco.2003.08.072
Joly F, Vardy J, Pintilie M, Tannock I (2007) Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. doi:10.1093/annonc/mdm121
Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244–250. doi:10.1200/jco.2014.56.2728
Kummar S, Gutierrez M, Doroshow JH, Murgo AJ (2006) Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 62:15–26. doi:10.1111/j.1365-2125.2006.02713.x
Le Tourneau C, Michiels S, Gan HK, Siu LL (2009) Reporting of time-to-event endpoints and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer. J Clin Oncol 27:5965–5971
Li J, Asabere A, Kelly S, Cho Y, Dua D, Bastian A (2015) Application of asco value framework evaluations of net health benefit for oncology drugs launched in the United States between 2013 and 2015. Value Health 18:A489. doi:10.1016/j.jval.2015.09.1352
Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P (2009) Comparison of registered and published primary outcomes in randomized controlled trials. JAMA 302:977–984. doi:10.1001/jama.2009.1242
Mathoulin-Pelissier S, Gourgou-Bourgade S, Bonnetain F, Kramar A (2008) Survival endpoint reporting in randomized cancer clinical trials: a review of major journals. J Clin Oncol 26:3721–3726. doi:10.1200/jco.2007.14.1192
Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6:409–414. doi:10.1038/nrc1883
Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, Stollenwerk B, Siebert U (2008) Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 24:371–383. doi:10.1017/s0266462308080495
Nelson NJ (2010) Circulating tumor cells: will they be clinically useful? J Natl Cancer Inst 102:146–148. doi:10.1093/jnci/djq016
Osoba D (2011) Health-related quality of life and cancer clinical trials therapeutic advances. Med Oncol 3:57–71. doi:10.1177/1758834010395342
Raphael J, Verma S (2015) Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome. Breast Cancer Res Treat 150:473–478. doi:10.1007/s10549-015-3342-2
Robertson JFR, Willsher PC, Cheung KL, Blarney RW (1997) The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33:1774–1779. doi:10.1016/s0959-8049(97)00178-0
Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM (2009) Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. PLoS Med 6:e1000144. doi:10.1371/journal.pmed.1000144
Saad ED, Buyse M (2012) Overall survival: patient outcome, therapeutic objective, clinical trial endpoint, or public health measure? J Clin Oncol 30:1750–1754. doi:10.1200/jco.2011.38.6359
Saad ED, Katz A, Buyse M (2010) Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 28:1958–1962. doi:10.1200/jco.2009.25.5414
Saito H, Gill CJ (2014) How frequently do the results from completed US clinical trials enter the public domain?–A statistical analysis of the ClinicalTrials.gov database. PLoS One 9:e101826. doi:10.1371/journal.pone.0101826
Sanoff HK, Chang Y, Lund JL, O’Neil BH, Dusetzina SB (2016) Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist. doi:10.1634/theoncologist.2015-0478
Sargent DJ, Hayes DF (2008) Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol 26:1922–1923. doi:10.1200/jco.2007.14.8064
Schilsky RL (2002) Endpoints in cancer clinical trials and the drug approval process. Clin Cancer Res 8:935–938
Schnipper LE, Davidson NE, Wollins DS et al (2015) American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol. doi:10.1200/jco.2015.61.6706
Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437. doi:10.1038/nrc3066
Stone A, Wheeler C, Barge A (2007) Improving the design of phase II trials of cytostatic anticancer agents. Contemp Clin Trials 28:138–145. doi:10.1016/j.cct.2006.05.009
Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate endpoints for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562–4568. doi:10.1200/jco.2006.08.1935
Thomas ES, Gomez HL, Li RK et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217. doi:10.1200/jco.2007.12.6557
Tuma RS (2006) Sometimes size doesn’t matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 98:1272–1274. doi:10.1093/jnci/djj403
U.S. Food and Drug Administration (2007) Guidance for Industry: clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/downloads/Drugs/Guidances/ucm071590.pdf. Accessed 20 June 2016
U.S. Food and Drug Administration (2011) FDA commissioner announces Avastin decision: drug not shown to be safe and effective in breast cancer patients
Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791. doi:10.1056/NEJMoa1209124
Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295:2727–2741 doi:10.1001/jama.295.23.joc60074
You B, Gan HK, Pond G, Chen EX (2012) Consistency in the analysis and reporting of primary endpoints in oncology randomized controlled trials from registration to publication: a systematic review. J Clin Oncol 30:210–216. doi:10.1200/JCO.2011.37.0890
Yu RX, Holmgren E (2007) Endpoints for agents that slow tumor growth. Contemp Clin Trials 28:18–24. doi:10.1016/j.cct.2006.05.011
Zarin DA, Tse T, Ide NC (2005) Trial registration at ClinicalTrials.gov between may and october 2005. N Engl J Med 353:2779–2787. doi:10.1056/NEJMsa053234
Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC (2011) The ClinicalTrials.gov results database—Update and key issues. N Engl J Med 364:852–860. doi:10.1056/NEJMsa1012065
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval and informed consent
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Seung Yeon Song and Heenam Seo have contributed equally to this study.
Rights and permissions
About this article
Cite this article
Song, S.Y., Seo, H., Kim, G. et al. Trends in endpoint selection in clinical trials of advanced breast cancer. J Cancer Res Clin Oncol 142, 2403–2413 (2016). https://doi.org/10.1007/s00432-016-2221-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-016-2221-5